Biocytogen is a global biotech company advancing antibody drug development through innovative technologies. Leveraging gene-editing expertise, it pioneered drug target knock-in humanized models and offers 3,000+ models via BioMice™, along with in vivo, ex vivo, and in vitro pharmacology and custom gene-editing services. Biocytogen drives fully human monoclonal antibody discovery and offers 400,000+ antibody sequences targeting 1,000 proteins through its RenBiologics™ sub-brand for global partnerships.